Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast ...

U.S. telehealth upstart Hims & Hers Health, Inc. is planning to enter the Canadian market with an eye to selling generic ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Laura Schmidt and colleagues identify systemic financial conflicts of interest that serve as a cautionary tale for users of medical guidelines Prescribing glucagon-like peptide 1 (GLP-1) receptor ...

The cruel costs of denying anti-obesity medication Joyce Linehan served as chief of policy and planning for former Boston mayor Martin J. Walsh..

Both Mounjaro and anti-obesity medication, Ozempic, are typically covered by insurance for people who have diabetes. Rosie O'Donnell gets political: Leaving US for second Trump presidency was ...